Latest News

Genetic Veterinary Sciences, Inc. launches genetic testing for cats and birds adding to their suite of brands

Genetic Veterinary Sciences Inc.®, the leader in canine genetic health, has launched two additional brands, AvianDx™ and CatScan™, to join their Paw Print Genetics® and Canine HealthCheck® suite of animal genetic health testing services. In addition to providing clinical genetic testing for canines, Genetic Veterinary Sciences will now offer services for pet birds and cats.

The first product for the AvianDx brand is their EarlyBird Sex Identification™ test. There are more than 10,000 species of birds throughout the world that are monomorphic, meaning that males cannot be distinguished from females based on physical characteristics. With AvianDx’s EarlyBird Sex Identification test, one can discover the sex of their bird with one simple test. Birds can be tested through a variety of samples that include eggshells, blood and feathers.

The CatScan is a genetic screen of more than 75 inherited diseases and traits commonly found in cats. The CatScan provides the largest menu of tests on the market and follows the published standards and guidelines for genetic testing of canines to provide highly accurate results. Once purchased, customers simply follow instructions on how to collect a DNA sample and send it to the CatScan laboratory with no veterinary visit required.  This testing allows cat owners to gain an understanding of their cat’s genetic health and be proactive with preventative care.

Blake Ballif, the Director of Operations at Genetic Veterinary Sciences, Inc. stated, “Paw Print Genetics is thrilled to now offer the highest quality diagnostic testing and carrier screening with world-class customer support to our feline and avian friends as well as our canine companions. Expanding into these markets has been a request of many of our canine customers and we look forward to helping people better understand the genetics of their cats and birds.”

In addition to AvianDx and CatScan, Genetic Veterinary Sciences, Inc. also owns two other brands, Paw Print Genetics and Canine HealthCheck. These additional brands allow them to continue to raise the standard in companion animal genetic testing, with their outstanding customer support.

For more information, visit,,, and


About Genetic Veterinary Sciences, Inc.

Located in Spokane, Washington, Genetics Veterinary Sciences, Inc. was founded in 2012. Genetic Veterinary Sciences, Inc. is dedicated to achieving optimal genetic health for your companion animals by providing outstanding resources for dog, cat and bird owners, breeders, trainers, and veterinarians.

For more information regarding this topic, please contact Jessica Pieros at

First of its Kind Checklist for Use in Canine Clinical Testing Labs Will Improve Quality in Rapidly Evolving Field of Genetic Testing for Dogs

Currently, there is no regulatory oversight for canine genetic testing laboratories. Paw Print Genetics, a division of Genetic Veterinary Sciences, Inc., along with Feragen, a canine testing facility in Austria, has published a follow up to their Standards and Guidelines for Canine Clinical Genetic Testing Laboratories in the journal Human Genetics. This follow up publishes the first checklist that can be used by clinical testing laboratories that deliver genetic results to dog owners and breeders to provide self-assessment and develop a baseline for quality assurance. The checklist provides the first step toward a standardize quality assurance program within canine clinical genetic testing laboratories.

Paw Print Genetics collaborated with Feragen and others in the fall of 2018, to create and publish the first set of standards and guidelines for canine testing laboratories based on well-established standards and guidelines developed by the American College of Medical Genetics and Genomics and adopted by human genetic testing laboratories for many years. The purpose of the standards and guidelines is to provide guidance and uniformity across all canine genetic testing laboratories to improve accuracy throughout the whole industry.

Along with creating a checklist, this follow up publication also addresses concerns raised among the canine community that includes issues such as rare or private mutations, genetic screening using array-based technologies, non-peer reviewed tests, and the clinical validity of specific mutations in certain breeds.

“As a board-certified geneticist, I understand the need for standards and guidelines to help pave the way for industry uniformity and to increase accuracy in clinical testing,” says Lisa Shaffer, PhD Paw Print Genetics’ Founder and CEO, “because genetic testing in dogs is direct-to-consumer, we have an even higher burden of excellence in testing, as we deal directly with the dog owner and breeder who rely on testing to inform them in their breeding programs.”

The Publication states that following the Standards and Guidelines and using the checklist is, “the responsible approach to providing the consumer the best care for their dogs”.

Shaffer concludes, “The use of genetic testing in dogs is useful to the breeder who wishes to avoid producing puppies with diseases, provides tests for the veterinarian confirming a clinical diagnosis and allows selection of dogs for various important duties within our society such as service dogs, K-9 and military dogs. Tools like our recommended standards and guidelines combined with this new checklist can help to make sure that genetic test results are accurate and can be relied upon for these and other important decisions.”

Both the published Standards and Guidelines and the follow up checklist can be found in the journal Human Genetics though the links below:


Standards and Guidelines:



Jessica Pieros

Paw Print Genetics Wins Patent Lawsuit Against Laboklin

Genetic Veterinary Sciences, DBA Paw Print Genetics announced today that a federal court in Norfolk, VA ruled as a matter of law following a three-day jury trial that claims 1-3 of a patent related to Hereditary Nasal Parakeratosis (HNPK) owned by the University of Bern, Switzerland and licensed to Laboklin, a German company, is invalid for failing to claim eligible subject matter.

Paw Print Genetics sought clarification from the courts in February 2017, asking for a declaratory judgment after receiving a cease and desist letter from Laboklin. The complaint alleges that claims covering routine and conventional methods of detecting disease (or risk factors for disease) are not eligible for patent protection. The suit alleges that Laboklin’s U.S. Patent No. 9,157,114, simply claims routine and well-known methods of detecting a naturally occurring mutation in a Labrador retriever and is therefore invalid. The Court agreed and decided the matter without submitting the question to the jury because the evidence presented permitted only one outcome.

Two important Supreme Court Rulings support Paw Print Genetics' position that the patent for detecting mutations for canine HNPK is invalid. In March of 2012, the Supreme Court of the United States decided Mayo v. Prometheus, a case concluding that "the processes claimed by the patents effectively claim natural laws or natural phenomena—namely, the correlations between thiopurine metabolite levels and the toxicity and efficacy of thiopurine drugs—and therefore are not patentable”. In another Supreme Court decision issued June, 2013, Molecular Pathology v. Myriad Genetics, the Court concluded that "Myriad did not create or alter either the genetic information encoded in the BRCA1 and BRCA2 genes or the genetic structure of the DNA. It found an important and useful gene, but groundbreaking, innovative, or even brilliant discovery does not by itself satisfy the §101 inquiry." The Court went on to say, "we hold that a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated."

Paw Print Genetics previously had won a lawsuit involving canine exercise induced collapse (EIC), which received a declaratory judgement of invalidity in March, 2015. In that case, the Honorable United States District Court Judge John R. Tunheim in the U.S. District Court of Minnesota, stated that "Here, the Court concludes that no inventive concept saves the ‘297 Patent from its focus on a patent-ineligible natural law. Because all that it adds to the natural law are well-known genetic detection methods, the Court finds the patent's eight claims to be invalid and will grant PPG's motion for partial summary judgment."

Similar to the EIC case, the Honorable United States District Court Judge Henry Coke Morgan, Jr., Senior United States District Judge in the U.S. District Court for the Eastern District of Virginia, Norfolk Division found US Patent ‘114 invalid due to ineligible subject matter. In this case, the patent attempted to pair well-known, conventional methods with a naturally occurring DNA sequence of the SUV39H2 gene. Mutations in theSUV39H2 gene are known to cause HNPK, a disease of Labrador retrievers in which the noses of affected dogs become dry, cracked and susceptible to infections. Testing for the mutation in Labrador retrievers can allow breeders to avoid producing puppies with this condition.

In a statement, Paw Print Genetics' founder and CEO, Dr. Lisa Shaffer said, "This legal declaration that the ‘114 patent for HNPK testing is invalid is a huge victory for dog owners and breeders, allowing them the choice to have accurate, high quality testing performed through our laboratory, ensuring access to everyone seeking testing for their dogs. We are proud to have been the one that fought this battle for all dog owners and breeders who need access to genetic testing for their pets. We will continue to fight for the rights to genetic testing, affordable pricing, and the highest quality standards so that all dog owners and breeders have access to accurate genetic information on their dogs."